David Shamblaw

1.2k total citations
7 papers, 379 citations indexed

About

David Shamblaw is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, David Shamblaw has authored 7 papers receiving a total of 379 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Infectious Diseases, 6 papers in Virology and 3 papers in Emergency Medicine. Recurrent topics in David Shamblaw's work include HIV/AIDS drug development and treatment (7 papers), HIV Research and Treatment (6 papers) and HIV/AIDS Research and Interventions (3 papers). David Shamblaw is often cited by papers focused on HIV/AIDS drug development and treatment (7 papers), HIV Research and Treatment (6 papers) and HIV/AIDS Research and Interventions (3 papers). David Shamblaw collaborates with scholars based in United States, United Kingdom and Germany. David Shamblaw's co-authors include Peter Ruane, Hui C. Liu, Jason Flamm, Scott McCallister, Edwin DeJesus, Moupali Das, Ramin Ebrahimi, Cheryl McDonald, Richard Elion and Brian P. Kearney and has published in prestigious journals such as AIDS, JAIDS Journal of Acquired Immune Deficiency Syndromes and Journal of the International AIDS Society.

In The Last Decade

David Shamblaw

7 papers receiving 376 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Shamblaw United States	6	341	239	143	48	31	7	379
Amanda Clarke United Kingdom	5	320 0.9×	215 0.9×	134 0.9×	57 1.2×	34 1.1×	6	398
Awny Farajallah United States	8	599 1.8×	408 1.7×	243 1.7×	85 1.8×	26 0.8×	12	649
David Piontkowsky United States	12	422 1.2×	269 1.1×	206 1.4×	77 1.6×	23 0.7×	27	458
Elisabetta Chiesa Italy	11	306 0.9×	242 1.0×	96 0.7×	63 1.3×	11 0.4×	17	351
Antonio Antela Spain	8	300 0.9×	214 0.9×	98 0.7×	57 1.2×	11 0.4×	22	353
Naomi Givens United Kingdom	9	566 1.7×	399 1.7×	200 1.4×	107 2.2×	30 1.0×	17	609
Ya-Pei Liu United States	10	465 1.4×	347 1.5×	167 1.2×	74 1.5×	30 1.0×	16	518
Gianmaria Baldin Italy	13	387 1.1×	294 1.2×	124 0.9×	84 1.8×	11 0.4×	50	457
Rima Acosta United States	11	474 1.4×	343 1.4×	243 1.7×	60 1.3×	23 0.7×	17	512
Anita Scribner United States	6	203 0.6×	156 0.7×	62 0.4×	48 1.0×	13 0.4×	7	245

Countries citing papers authored by David Shamblaw

Since Specialization

Citations

This map shows the geographic impact of David Shamblaw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Shamblaw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Shamblaw more than expected).

Fields of papers citing papers by David Shamblaw

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Shamblaw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Shamblaw. The network helps show where David Shamblaw may publish in the future.

Co-authorship network of co-authors of David Shamblaw

This figure shows the co-authorship network connecting the top 25 collaborators of David Shamblaw. A scholar is included among the top collaborators of David Shamblaw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Shamblaw. David Shamblaw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Huhn, Gregory, David Shamblaw, Jean‐Guy Baril, et al.. (2019). Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate. Open Forum Infectious Diseases. 7(1). ofz472–ofz472. 33 indexed citations

Mills, Anthony, Gordon Crofoot, Cheryl McDonald, et al.. (2015). Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 69(4). 439–445. 121 indexed citations

Tebas, Pablo, Martin Fisher, Brian Gazzard, et al.. (2013). Efficacy of switching to rilpivirine/emtricitabine/tenofovir DF from boosted PI in HIV-1 virologically suppressed patients with or without the K103N. Journal of the International AIDS Society. 16(Suppl 1). 2 indexed citations

Palella, Frank J., Martin Fisher, Pablo Tebas, et al.. (2013). Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS. 28(3). 335–344. 92 indexed citations

Fisher, Martin, Frank J. Palella, Pablo Tebas, et al.. (2012). SPIRIT: switching to emtricitabine/rilpivirine/tenofovir DF single‐tablet regimen from boosted protease inhibitor maintains HIV suppression at week 48. Journal of the International AIDS Society. 15(S4). 1–1. 11 indexed citations

Cohen, Calvin, Richard Elion, Peter Ruane, et al.. (2011). Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 25(6). F7–F12. 93 indexed citations

DeJesus, Edwin, Peter Ruane, Cheryl McDonald, et al.. (2008). Impact of Switching Virologically Suppressed, HIV-1-Infected Patients from Twice-Daily Fixed-Dose Zidovudine/Lamivudine to Once-Daily Fixed-Dose Tenofovir Disoproxil Fumarate/Emtricitabine. HIV Clinical Trials. 9(2). 103–114. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact